Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant data. One of our top-selling.
Cerecor Announces $43 Million Deal with AYTU BioScience to Sell Pediatric Portfolio and Advance Towards NDA
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
Aurinia Appoints Joe Miller as Chief Financial Officer APRIL 27, 2020 VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical [….]
Five Biotechs Poised to Advance Their Rare Disease Programs in 2020 On the cusp of rare disease month, we’re checking in with Maryland biotech companies at the forefront of rare [….]
Why Developing Cures for Rare Disease Isn’t So Rare Anymore These Six Maryland Biotech Companies Are Seeing Success in Targeting Rare Diseases September 3, 2019 Groundbreaking technology and scientific advancements, [….]